| ISIN | LU1949848128 |
|---|---|
| Valorennummer | |
| Bloomberg Global ID | |
| Fondsname | DNCA INVEST - SRI NORDEN EUROPE Class ID |
| Fondsanbieter |
DNCA Finance Luxembourg Branch
Telefon: +352 27 62 13 07 1 Place d'Armes L-1136 Luxembourg E-Mail: dncabelux@dnca-investments.com Web: www.dnca-investments.com |
| Fondsanbieter | DNCA Finance Luxembourg Branch |
| Vertreter in der Schweiz |
Reyl & Cie S.A. Genève Telefon: +41 22 816 80 00 |
| Distributor(en) | BNP Paribas Securities Services Luxembourg |
| Anlagekategorie | Aktienfonds |
| EFC-Kategorie | |
| Anteilskategorie | Distribution |
| Domizilland | Luxemburg |
| Konditionen bei der Ausgabe | Kombination von Ausgabekommission zugunsten der Fondsleitung und Transaktionsgebühr zugunsten des Fonds |
| Konditionen bei der Rücknahme | Kombination von Rücknahmekommission zugunsten der Fondsleitung und Transaktionsgebühr zugunsten des Fonds |
| Investment-Strategie *** | The Sub-Fund seeks to outperform the following composite net return index denominated in Euro: 35% MSCI Nordic, 25% DAX, 15% SMI, 15% AEX, 10% MSCI UK TR UK Net Local Currency calculated with dividends net of withholding taxes reinvested, over the recommend investment term. Investors’ attention is drawn to the fact that the management style is discretionary and integrates environmental, social / societal and governance (ESG) criteria. Investment Strategy: The Sub-Fund will invest at all times at least 90% of its total assets in equities of issuers listed on North European stock exchanges (Britain, Ireland, Benelux, Norway, Sweden, Finland, Denmark, Germany, Swiss, Austria), in all market capitalisation or exercising the preponderant part of their economic activities in the North of Europe. |
| Besonderheiten |
| Aktueller Preis * | 132.15 EUR | 19.01.2026 |
|---|---|---|
| Vorheriger Preis * | 134.99 EUR | 16.01.2026 |
| 52 Wochen Hoch * | 146.89 EUR | 26.02.2025 |
| 52 Wochen Tief * | 119.34 EUR | 09.04.2025 |
| NAV * | 132.15 EUR | 19.01.2026 |
| Ausgabepreis * | ||
| Rücknahmepreis * | ||
| Schlusskurs * | ||
| Indikativer Minimalpreis | ||
| Fondsvermögen *** | 335'692'396 | |
| Anteilsklassevermögen *** | 127'534'748 | |
| Trading Information SIX | ||
| YTD-Performance | +2.55% |
31.12.2025 - 19.01.2026
31.12.2025 19.01.2026 |
|---|---|---|
| YTD-Performance (in CHF) | +2.27% |
31.12.2025 - 19.01.2026
31.12.2025 19.01.2026 |
| 1 Monat | +3.59% |
19.12.2025 - 19.01.2026
19.12.2025 19.01.2026 |
| 3 Monate | +0.89% |
20.10.2025 - 19.01.2026
20.10.2025 19.01.2026 |
| 6 Monate | -4.45% |
21.07.2025 - 19.01.2026
21.07.2025 19.01.2026 |
| 1 Jahr | -5.78% |
20.01.2025 - 19.01.2026
20.01.2025 19.01.2026 |
| 2 Jahre | +7.39% |
19.01.2024 - 19.01.2026
19.01.2024 19.01.2026 |
| 3 Jahre | +13.56% |
19.01.2023 - 19.01.2026
19.01.2023 19.01.2026 |
| 5 Jahre | +10.19% |
19.01.2021 - 19.01.2026
19.01.2021 19.01.2026 |
| Kapitalbeteiligungsquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anteil am Gesamtvermögen in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Immobilienquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ASML Holding NV | 4.32% | |
|---|---|---|
| AstraZeneca PLC | 4.30% | |
| UCB SA | 4.29% | |
| Alm Brand AS | 4.24% | |
| NKT AS | 4.21% | |
| SAP SE | 4.07% | |
| Sartorius Stedim Biotech SA | 3.81% | |
| Galderma Group AG Registered Shares | 3.79% | |
| Novonesis (Novozymes) B Class B | 3.79% | |
| Lonza Group Ltd | 3.78% | |
| Letzte Daten-Aktualisierung | 31.12.2025 | |
| TER | |
|---|---|
| Datum TER | |
| Performance Fee *** | |
| PTR | |
| Max. Management Fee *** | 1.00% |
| Ongoing Charges *** | 1.06% |
|
SRRI ***
|
|
| Datum SRRI *** | 31.12.2025 |